Bavarian Nordic Launches Second DKK 250 Million Share Buyback Tranche Under DKK 750 Million Programme

16 November 2026 | Monday | News

The Danish biotechnology company will repurchase up to two million shares between 13 November 2026 and 15 January 2027, with Danske Bank managing the transactions. The buyback forms part of Bavarian Nordic’s DKK 750 million programme aimed at adjusting its capital structure through the planned cancellation of repurchased shares
Image Source: Public Domain

Image Source: Public Domain

Bavarian Nordic A/S (OMX: BAVA) launches the second tranche of the share buy-back program announced on August 21, under which the Company intends to repurchase own shares for up to DKK 750 million. The second tranche will comprise buy-back of shares for up to DKK 250 million.

The purpose of the new share buy-back program is to adjust the capital structure, through subsequent cancellation of shares repurchased under this program, subject to any necessary additional corporate resolutions, as applicable.

The share buy-back program is initiated pursuant to the authorization granted at the annual general meeting on April 21, 2026, and in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation.

Bavarian Nordic has appointed Danske Bank as lead manager to execute the share buy-back in accordance with the terms of the program and with authorization to make trading decisions independently and without influence of Bavarian Nordic.

Terms of the program

  • The share buy-back program will commence on November 13, 2026, and will be completed by January 15, 2027, at the latest.
  • Shares of up to a maximum aggregate purchase price of DKK 250 million may be repurchased.
  • A maximum of 2,000,000 shares will be repurchased within the duration of the program.
  • The maximum number of shares, which can be purchased on any single trading day, may not exceed 25% of the average daily trading volume of Bavarian Nordic shares traded on Nasdaq Copenhagen during the preceding 20 trading days before the trading day.
  • The shares may not be purchased at a price exceeding the higher of the price of the last independent trade, or the highest independent purchase bid on Nasdaq Copenhagen.

Details of transactions under the program will be published weekly after commencement and at completion of the program.

Prior to the initiation of this program, Bavarian Nordic held 4,664,037 treasury shares, corresponding to 5.88% of the Company’s share capital.

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close